Total submissions: 1
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Prevention |
RCV003904619 | SCV004726098 | pathogenic | COL7A1-related disorder | 2024-02-23 | no assertion criteria provided | clinical testing | The COL7A1 c.7096G>T variant is predicted to result in the amino acid substitution p.Gly2366Cys. This variant has been reported in the compound heterozygote state in an individual with autosomal recessive dystrophic epidermolysis bullosa (Sawamura et al. 2005. PubMed ID: 16189623; Almaani et al. 2011. PubMed ID: 21448560). Of note, other amino acid substitutions involving this residue (p.Gly2366Ser; p.Gly2366Arg; p.Gly2366Asp; p.Gly2366Ala; p.Gly2366Val) were found in individuals with autosomal dominant or recessive dystrophic epidermolysis bullosa (Hashimoto et al. 1999. PubMed ID: 10232406; Lucky et al. 2018. PubMed ID: 29334134; Escámez et al. 2010. PubMed ID: 20184583; Chen et al. 2022. PubMed ID: 36287101; Chuang et al. 2004. PubMed ID: 15115517). The amino acid residue p.Gly2366Cys resides within the triple helical domain of the COL7A1 protein (amino acids 1254-2783). Glycine substitutions within this domain affect the folding and secretion of type VII collagen, and pathogenic variants altering glycine residues have been reported in individuals with COL7A1-related disorders (Dang and Murrell. 2008. PubMed ID: 18558993; Abu Sa'd et al. 2006. PubMed ID: 16439963; Almaani et al. 2011. PubMed ID: 21448560; Vahidnezhad et al. 2017. PubMed ID: 27899325). This variant has not been reported in a large population database (http://gnomad.broadinstitute.org), indicating this variant is rare. This variant is interpreted as pathogenic. |